Operator of a biopharmaceutical company focused on developing non-toxic, curative therapies for challenging medical conditions, including cancer, infectious diseases, sepsis, and neurological disorders. The company integrates internal research, collaborations, partnerships, and acquisitions to expedite the development of transformative medicines, emphasizes patient-centric approaches to reverse diseases at molecular and cellular levels while reducing organ toxicities, and specializes in creating small molecules that target multiple mutated genes and signaling pathways with a single, non-toxic agent.